264 related articles for article (PubMed ID: 34776794)
1. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
2. Fatty acid metabolism-related molecular subtypes and a novel model for predicting prognosis in bladder cancer patients.
Su WT; Chen JY; Sun JB; Huang QI; Ke ZB; Chen SH; Lin YZ; Xue XY; Wei Y; Xu N
J Biosci; 2024; 49():. PubMed ID: 38186002
[TBL] [Abstract][Full Text] [Related]
3. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
4. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a molecular prognostic index of bladder cancer based on immunogenomic landscape analysis.
Xu N; Ke ZB; Lin XD; Chen YH; Wu YP; Chen Y; Dong RN; Chen SH; Li XD; Wei Y; Zheng QS; Lin YZ; Xue XY
Cancer Cell Int; 2020; 20():302. PubMed ID: 32675942
[TBL] [Abstract][Full Text] [Related]
6. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
7. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
8. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer.
Yang Y; Yu J; Xiong Y; Xiao J; Dai D; Zhang F
Pathol Oncol Res; 2022; 28():1610267. PubMed ID: 35685866
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
11. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.
Zhao X; Tang Y; Ren H; Lei Y
Biomed Res Int; 2020; 2020():9143695. PubMed ID: 33204728
[TBL] [Abstract][Full Text] [Related]
12. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
13. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
Sun X; Xin S; Jin L; Zhang Y; Ye L
Bioengineered; 2022 May; 13(5):13986-13999. PubMed ID: 35758021
[TBL] [Abstract][Full Text] [Related]
14. Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer.
Luo Y; Chen L; Zhou Q; Xiong Y; Wang G; Liu X; Xiao Y; Ju L; Wang X
J Cell Mol Med; 2020 Nov; 24(22):13370-13382. PubMed ID: 33048468
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide screening of abberant methylated drivers combined with relative risk loci in bladder cancer.
Zhang C; Shen K; Zheng Y; Qi F; Luo J
Cancer Med; 2020 Jan; 9(2):768-782. PubMed ID: 31794632
[TBL] [Abstract][Full Text] [Related]
16. Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.
Chen Z; Ou Y; Ye F; Li W; Jiang H; Liu S
J Cancer Res Clin Oncol; 2024 May; 150(5):264. PubMed ID: 38767747
[TBL] [Abstract][Full Text] [Related]
17. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
18. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
Jiang L; Chen S; Pan Q; Zheng J; He J; Sun J; Han Y; Yang J; Zhang N; Fu G; Gao F
BMC Cancer; 2022 Jun; 22(1):676. PubMed ID: 35725413
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
